Fresenius And Formycon File Ustekinumab In US

Firms Submit BLA For FYB202 Stelara Biosimilar To FDA; Launch Anticipated In April 2025

Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.

Sign outside of FDA's headquarters in White Oak, MD
Fresenius Kabi and Formycon have submitted their filing to the FDA • Source: Alamy

Fresenius Kabi and Formycon have announced that the US Food and Drug Administration has accepted their filing for a biosimilar rival to Stelara (ustekinumab).

The news follows a recent filing for the pair’s FYB202 version in Europe. (Also see "Fresenius And Formycon File...

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.